Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Gary de Jesus"'
Autor:
Veerendra Munugalavadla, Gary de Jesus, Aleksandra Markovets, Qinwen Liu, Oliver Venn, Rafael White, Giulia Fabbri, Paul Labrousse, Dan Stetson, Brian Dougherty, Darren Hodgson, Jill Walker, Anas Younes, Daniel Auclair
Publikováno v:
Cancer Research. 83:3369-3369
Introduction: Minimal or measurable residual disease (MRD) is an emerging independent predictor of progression-free and overall survival in several hematologic diseases. Despite many different methods used in clinical trials, few assays have clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7790fed47f9602e932cbf7c70ba5a8d9
https://doi.org/10.1158/1538-7445.am2023-3369
https://doi.org/10.1158/1538-7445.am2023-3369
Autor:
Graham Brock, Kathleen A. Burke, Todd Covey, Veerendra Munugalavadla, Brian Law, Richard R. Furman, Kyoko Yamaguchi, Tracy Clevenger, Jean Cheung, Melanie M. Frigault, Phuong Do, Michael Gulrajani, Elena Bibikova, Jennifer R. Brown, Gary De Jesus, John C. Byrd
Publikováno v:
Blood. 134:2571-2571
Background: Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase (BTK) inhibitor developed to minimize off-target activity. Acalabrutinib monotherapy shows promising safety and efficacy in CLL (Ghia et al 2019). However, a few
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8eea4831a9b887ec0e8be798fc46db74
https://doi.org/10.1182/blood-2019-128872
https://doi.org/10.1182/blood-2019-128872